Dr. Jonathan D. Licht Appointed President of Van Andel Institute
GRAND RAPIDS, Mich. — Van Andel Institute has officially announced the appointment of Dr. Jonathan D. Licht as the new president and chief scientific officer, effective in early 2026. This prestigious role reflects Dr. Licht's significant expertise in the field as an internationally recognized physician-scientist.
Strengthening Research Programs
Dr. Licht's extensive experience in building impactful research initiatives is anticipated to bolster the Institute's mission to enhance the health of future generations. His groundbreaking research within the realm of blood cancers, particularly leukemia, has revolutionized the understanding of these diseases and their progression.
Legacy of Leadership
Dr. Licht succeeds Dr. Peter A. Jones, who served as president since 2013. Under Dr. Jones's leadership, the Institute flourished, establishing itself as a premier leader in cancer epigenetics. This field studies how gene expression is regulated without altering DNA sequences, a crucial factor in understanding various diseases, including cancer.
Continued Research Excellence
Dr. Jones will remain at Van Andel Institute as a professor within the Department of Epigenetics while continuing his research efforts. He also co-leads the innovative Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team, which evaluates promising cancer therapy approaches.
Expressing excitement about Dr. Licht's appointment, VAI CEO and Chairman David Van Andel stated, "We are thrilled to welcome Dr. Licht to Van Andel Institute. His proven leadership, innovative research, and strategic vision are vital as we advance our mission further. We also owe a great debt to Dr. Jones for his leadership over the past decade, which has been marked by outstanding growth and scientific achievements."
A Distinguished Career in Cancer Research
With a strong academic foundation, Dr. Licht earned his B.S. from the State University of New York at Stony Brook and completed his M.D. at Columbia University. His impressive career includes leading roles at distinguished institutions, including serving on the faculty at Mount Sinai for over 15 years before directing the Robert H. Lurie Cancer Center at Northwestern University.
Innovative Laboratory Research
Dr. Licht's laboratory is dedicated to exploring the links between epigenetic irregularities and the development of hematological malignancies. His research findings have notably identified critical mutations associated with childhood B cell acute lymphocytic leukemia, presenting potential new therapeutic avenues.
Vision for the Future
On his new role, Dr. Licht remarked, "I am honored to succeed Dr. Peter Jones at Van Andel Institute. This dynamic institution stands at the forefront of biomedical research, and I eagerly anticipate collaborating with the VAI community to foster innovative health initiatives, including intersections among cancer research, neurodegeneration, and metabolism."
An Esteemed Contributor to Science
Dr. Licht has cultivated an exceptional career, authoring over 240 scholarly publications with significant citation impact. His leadership positions within prominent organizations such as the American Society of Hematology and the American Association for Cancer Research further highlight his commitment to advancing cancer research. His accolades include being a Leukemia and Lymphoma Society Scholar and a respected mentor for emerging scientists.
About Van Andel Institute
Founded in 1996 by the Van Andel family, the Van Andel Institute is dedicated to pioneering biomedical research and educational endeavors. Situated in Grand Rapids, Michigan, VAI unites talented scientists and educators committed to making significant advancements in health sciences while nurturing future generations through innovative educational opportunities.
Frequently Asked Questions
Who is Dr. Jonathan D. Licht?
Dr. Jonathan D. Licht is a renowned physician-scientist appointed as the new president and chief scientific officer of Van Andel Institute, bringing extensive expertise in cancer research.
What is Van Andel Institute?
Van Andel Institute (VAI) is a leading biomedical research organization focused on improving health through research and education, established in 1996 in Grand Rapids, Michigan.
What are Dr. Licht's contributions to cancer research?
Dr. Licht has made significant advancements in understanding blood cancers and identified mutations linked to treatment resistance in various types of leukemia.
What will Dr. Licht's role involve at VAI?
As president, Dr. Licht will advance the Institute's mission, focusing on enhancing research programs and fostering impactful collaborations for innovative health solutions.
How has VAI evolved under Dr. Jones's leadership?
Under Dr. Jones, VAI has grown into a notable institution in the field of cancer epigenetics and established itself as a significant player in biomedical research.
